Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases

Inclusion Criteria:

* Histological confirmation of colorectal adenocarcinoma
* Metastatic colorectal cancer involving the lung classified as determined by the treating clinical team
* Diagnosis of colorectal metastasis to lung made either histologically with trans-thoracic needle biopsy or clinically based on radiographic imaging
* Identification as a medically appropriate candidate for surgical resection of the lung metastasis (metastases) according to the evaluating cardiothoracic surgeon. Standard justification for deeming a patient medically operable based on:

  * Pulmonary reserve adequate to tolerate complete resection of all intrathoracic disease, as deemed by thoracic surgeon, which may be determined by:

    * Baseline forced expiratory volume in one second (FEV1) \> 40% predicted
    * Post-operative predicted FEV1 \> 30% predicted
    * Diffusion capacity of the lung for carbon monoxide (DLCO) \> 40% predicted
    * Absent baseline hypoxemia and/or hypercapnia
    * Exercise oxygen consumption \> 50% predicted
    * Absent severe pulmonary hypertension
    * Absent severe cerebral, cardiac, or peripheral vascular disease
    * Absent severe chronic heart disease
  * Ability to tolerate surgical resection and acceptable operative risk as deemed by thoracic surgeon based on performance status and medical comorbidities
* Identification as a medically appropriate candidate for systemic chemotherapy at the discretion of the evaluating medical oncologist
* Resection/definitive therapy of primary colorectal tumor with no suspicion of recurrence. Prior radiation to a rectal adenocarcinoma is permitted
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Ability to provide informed consent for participation
* Leukocytes \>= 2,000/mcL
* Absolute neutrophil count \>= 1,000/mcL
* Hemoglobin \>= 9.0 gm/dL
* Platelet count \>= 100,000/mcL
* Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL)
* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x ULN
* Serum creatinine =\< 1.5 x ULN OR creatinine clearance (CrCl \>= 50 mL/min (if using the Cockcroft-Gault formula)
* Patients (men and women) of child bearing potential should use an effective (for them) method of birth control throughout their participation in this study

Exclusion Criteria:

* Tumor involvement at other metastatic sites (e.g., liver, distant lymph nodes) that has not been definitively treated. Prior surgical resection for metastatic disease at other (non-pulmonary) sites is permitted
* Presence of intact primary colorectal adenocarcinoma (or of an anastomotic recurrence)
* Previous radiotherapy to a lung metastasis that is still detectable radiographically
* Known dihydropyrimidine dehydrogenase (DPD) deficiency that would preclude the patient from tolerating 5- fluorouracil chemotherapy
* Prior intolerance of systemic therapies used as standard regimens in the treatment of metastatic CRC that would prohibit further receipt of systemic chemotherapy and/or biologic agents -e.g.,5-fluorouracil, oxaliplatin, irinotecan, anti-VEGF therapies (e.g., bevacizumab, ramucirumab), or anti-EGFR therapies (e.g., cetuximab, panitumumab, for patients with RAS wild-type colorectal tumors)
* Prior therapy with regorafenib or trifluridine/tipiracil (TAS-102) for metastatic/unresectable colorectal cancer
* Synchronous primary or prior malignancy in the past 5 years other than non-melanomatous skin cancer or in situ cancer
* Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus